Understanding how Aspergillus fumigatus resists antifungal treatment
Non-cyp51A-mutation Mediated Triazole Resistance in Aspergillus fumigatus
This study is looking into how certain genetic changes in a fungus called Aspergillus fumigatus make it resistant to triazole medications, which are used to treat infections, so that we can find better ways to help patients get the effective treatment they need.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10788331 on NIH RePORTER |
What this research studies
This research investigates the genetic and molecular mechanisms behind triazole resistance in Aspergillus fumigatus, a fungus that can cause serious infections. The team aims to identify specific genetic changes that contribute to this resistance, focusing on factors like sterol biosynthesis and triazole transport. By uncovering these mechanisms, the research seeks to enhance antifungal therapies and ensure that triazole medications remain effective for treating infections. Patients may benefit from improved treatment options as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with infections caused by Aspergillus fumigatus, particularly those who have shown resistance to triazole antifungal medications.
Not a fit: Patients with infections caused by other types of fungi or those who do not have Aspergillus infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antifungal treatments for patients suffering from Aspergillus infections.
How similar studies have performed: Other research has shown success in understanding antifungal resistance mechanisms, but this specific focus on non-cyp51A-mediated resistance is relatively novel.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Fortwendel, Jarrod R. — University of Tennessee Health Sci Ctr
- Study coordinator: Fortwendel, Jarrod R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.